
Product Data Sheet

Brilliant Violet 510[™] anti-human CD206 (MMR)

Catalog # / Size:	2205690 / 100 tests 2205685 / 25 tests	
Clone:	15-2	Relative Cell Number
Isotype:	Mouse IgG1, κ	
Immunogen:	Purified human mannose receptor	
Reactivity:	Human	
Preparation:	The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510 [™] under optimal conditions. The solution is free of unconjugated Brilliant Violet 510 [™] and unconjugated antibody.	
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).	GM-CSF periphe stained Brilliant histogra
Concentration:	Lot-specific	



SF stimulated (3 days) human eral blood monocytes were d with CD206 (clone 15-2) nt Violet 510™ (filled histogram) or mouse IgG1

. . Δ

Applications:		
Applications:	Flow Cytometry	
Recommended Usage:	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells or 5 μ l per 100 μ l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.	
	Brilliant Violet 510 [™] excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510 [™] is a trademark of Sirigen Group Ltd.	
	This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.	
Application Notes:	The 15-2 antibody blocks the interaction of MMR with its ligand, and inhibits mannose receptor-mediated degradation of t-PA by macrophages. Additional reported applications of this antibody (for the relevant formats) include: Western blotting ¹ , blocking of ligand binding ^{1,2} , immunofluorescence ³ , and immunohistochemical staining of acetone-fixed frozen tissue sections ¹ .	
Application References:	 Mason D, <i>et al.</i> Eds. 2002. Leukocyte Typing VII. Oxford University Press. p303 Wileman TE, <i>et al.</i> 1986. <i>P. Natl. Acad. Sci. USA</i> 83:2501. Apostolopoulos V and McKenzie IF. 2001. <i>Curr. Mol. Med.</i> 1:46 	
accorrebuica aply. Not far diagnactic usa. Nat far racala. Sany Piatashnalagy Inc. will not be hald rasponsib		

For research use only. Not for diagnostic use. Not for resale. Sony Biotechnology Inc. will not be held responsible for patent infringement or other violations that may occur with the use of our products. Sony Biotechnology Inc. 1730 North First Street, San Jose, CA 95112 www.sonybiotechnology.com

- **Description:** Macrophage mannose receptor (MMR) is a 162-175 kD type I membrane protein also known as CD206, MRC1, or mannose receptor (MR). It is a pattern recognition receptor (PRR) that belongs to C-type lectin superfamily. MMR is expressed on macrophages, dendritic cells, and hepatic or lymphatic endothelial cells, but not on monocytes. MMR recognizes a range of microbial carbohydrates bearing mannose, fucose, or N-acetyl glucosamine. MMR mediates endocytosis and phagocytosis, induces activation of macrophages and antigen presentation, plays an important role in host defense, and provides a link between innate and adaptive immunity.
- Antigen
 1. Mason D, *et al.* Eds. 2002. Leukocyte Typing VII. Oxford University Press. p303
 References:
 2. Wileman TE, *et al.* 1986. *P. Natl. Acad. Sci. USA* 83:2501.
 - 3. Apostolopoulos V and McKenzie IF. 2001. Curr. Mol. Med. 1:46